GeoVax completes warrant inducement, collects about $3.6 million

GeoVax Labs, Inc. (Nasdaq: GOVX) disclosed in an 8-K filed August 28, 2026 that on August 25, 2026 it entered into a warrant exercise inducement agreement with a holder of several existing warrant series. The holder agreed to exercise for cash existing warrants covering an aggregate of 5,697,628 shares of common stock, in exchange for new warrants to purchase up to 11,395,256 shares at an exercise price of $0.64 per share, exercisable once required stockholder approval is obtained and expiring five years from issuance.¹

GeoVax collected roughly $3,646,482 in gross proceeds from the exercised warrants, before fees and other offering costs.¹ The company said the new warrants are substantially identical to the ones that were exercised.¹

A.G.P./Alliance Global Partners was engaged as exclusive financial advisor for the transaction, earning a cash fee equal to 7.0% of gross proceeds plus up to $40,000 in reimbursed legal expenses.¹ The new warrants were issued on August 26, 2026.¹ GeoVax said it plans to use the net proceeds for general corporate purposes.¹

GeoVax also agreed to file a registration statement within 30 days of the inducement letter to cover resale of the shares underlying the new warrants, and to keep it effective until the warrants are no longer held.¹ Separately, the company committed to holding a stockholder meeting by October 29, 2026 to seek approval needed for the new warrants to become exercisable.¹

Beyond the financing, the filing recaps GeoVax's pipeline. Its lead program, GEO-MVA, is a Modified Vaccinia Ankara-based vaccine for mpox and smallpox advancing under an expedited pathway, with a pivotal Phase 3 trial planned for the second half of 2026.¹ In oncology, its Gedeptin gene-directed enzyme prodrug therapy has completed a Phase 1/2 trial in advanced head and neck cancer and is being moved into combination approaches.¹